TapewireFind a company

person · Reporting owner

Dickinson Andrew D

Disclosed activity across 1 company

Tapewire entity
14295
SEC CIK
0001310204

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
GILEAD SCIENCES, INC.GILD · Entity 405Chief Financial OfficerSeptember 15, 2026September 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GILEAD SCIENCES, INC.

Report date September 15, 2026 · Filed September 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect164,096 Reported balance After 2026-09-15 transaction · row 1
1 source row

Row 1 · 2026-09-15 · Sale · Disposed 3,000 · Balance 164,096

F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 10, 2022 Filed Jun 14, 2022 00:13 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 3,646 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-017336 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,999

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Read SEC document
March 10, 2022 Filed Mar 15, 2022 17:34 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantNon-qualified Stock Option (Right to Buy) · Derivative 157,030 $0.00 Strike: $57.92 $0.00
Disclosure

SEC source: 0001127602-22-009273 · form4.xml · derivative · entry 9

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,030

Underlying: Common Stock · 157,030 shares

Expires 2032-03-10

F4 · derivative.exercise_date: The options have a four year vesting schedule. 25% vest on the first anniversary date of the date grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
March 10, 2022 Filed Mar 15, 2022 17:34 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantRestricted Stock Unit · Derivative 25,465 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-009273 · form4.xml · derivative · entry 8

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,124

Underlying: Common Stock · 25,465 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
March 10, 2022 Filed Mar 15, 2022 17:34 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 4,108 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-009273 · form4.xml · derivative · entry 7

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,659

Underlying: Common Stock · 4,108 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
March 10, 2022 Filed Mar 15, 2022 17:34 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 3,025 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-009273 · form4.xml · derivative · entry 6

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,767

Underlying: Common Stock · 3,025 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

Read SEC document
March 10, 2022 Filed Mar 15, 2022 17:34 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 768 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-009273 · form4.xml · derivative · entry 5

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,792

Underlying: Common Stock · 768 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

Read SEC document
March 10, 2022 Filed Mar 15, 2022 17:34 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 3,602 $57.92 $208,627.84
Disclosure

SEC source: 0001127602-22-009273 · form4.xml · nonDerivative · entry 4

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,005

Read SEC document
March 10, 2022 Filed Mar 15, 2022 17:34 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 4,108 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-009273 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,607

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Read SEC document
March 10, 2022 Filed Mar 15, 2022 17:34 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 3,025 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-009273 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,499

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Read SEC document
March 10, 2022 Filed Mar 15, 2022 17:34 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 768 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-009273 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,474

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Read SEC document
February 15, 2022 Filed Apr 14, 2022 00:37 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantCommon Stock 348 $52.13 $18,141.41
Disclosure

SEC source: 0001127602-22-011957 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,353

F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2021 through February 15, 2022. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2022.

Read SEC document
February 06, 2022 Filed Feb 9, 2022 01:25 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 1,817 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-003847 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,560

Underlying: Common Stock · 1,817 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

Read SEC document
February 06, 2022 Filed Feb 9, 2022 01:25 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 767 $63.90 $49,011.30
Disclosure

SEC source: 0001127602-22-003847 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,706

Read SEC document
February 06, 2022 Filed Feb 9, 2022 01:25 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 1,817 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-003847 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,473

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Read SEC document
January 26, 2022 Filed Jan 29, 2022 01:44 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 3,616 $67.34 $243,501.44
Disclosure

SEC source: 0001127602-22-002463 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,656

Read SEC document
January 26, 2022 Filed Jan 29, 2022 01:44 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantCommon Stock 13,156 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-002463 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,272

F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 6, 2019. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

Read SEC document
January 26, 2022 Filed Jan 29, 2022 01:44 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantCommon Stock 19,020 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-002463 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,116

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2020, and March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:50 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 1,913 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-029039 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,377

Underlying: Common Stock · 1,913 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:50 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 870 $67.32 $58,568.40
Disclosure

SEC source: 0001127602-21-029039 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,015

Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:50 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 1,913 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-029039 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,885

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

Read SEC document
August 15, 2021 Filed Aug 24, 2021 22:08 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantCommon Stock 1 $55.08 $55.08
Disclosure

SEC source: 0001127602-21-024261 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,972

F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of February 16, 2021 through August 15, 2021. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 16, 2021.

Read SEC document
June 10, 2021 Filed Jun 14, 2021 20:52 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 3,646 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-019794 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,290

Underlying: Common Stock · 3,646 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

Read SEC document
June 10, 2021 Filed Jun 14, 2021 20:52 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 1,605 $69.29 $111,210.45
Disclosure

SEC source: 0001127602-21-019794 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,971

Read SEC document
June 10, 2021 Filed Jun 14, 2021 20:52 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 3,646 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-019794 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,576

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 10, 2021 Filed Mar 13, 2021 00:33 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 3,794 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-010482 · form4.xml · derivative · entry 6

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,936

Underlying: Common Stock · 3,794 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F3 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F6 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

Read SEC document
March 10, 2021 Filed Mar 13, 2021 00:33 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantRestricted Stock Unit · Derivative 16,430 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-010482 · form4.xml · derivative · entry 5

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,730

Underlying: Common Stock · 16,430 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F3 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F5 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
March 10, 2021 Filed Mar 13, 2021 00:33 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantNon-qualified Stock Option (Right to Buy) · Derivative 95,620 $63.91 Strike: $63.91 $6,111,074.20
Disclosure

SEC source: 0001127602-21-010482 · form4.xml · derivative · entry 4

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,620

Underlying: Common Stock · 95,620 shares

Expires 2031-03-10

F4 · derivative.exercise_date: The options have a four year vesting schedule. 25% vest on the first anniversary date of the date grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
March 10, 2021 Filed Mar 13, 2021 00:33 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 1,771 $63.91 $113,184.61
Disclosure

SEC source: 0001127602-21-010482 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,930

Read SEC document
March 10, 2021 Filed Mar 13, 2021 00:33 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 3,794 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-010482 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,701

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

Read SEC document
February 15, 2021 Filed Mar 13, 2021 00:33 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantCommon Stock 364 $56.86 $20,695.77
Disclosure

SEC source: 0001127602-21-010482 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,907

F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2020 through February 15, 2021. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's stock on February 15, 2021.

Read SEC document
February 06, 2021 Filed Feb 10, 2021 00:41 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 1,818 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-004786 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,300

Underlying: Common Stock · 1,818 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

Read SEC document
February 06, 2021 Filed Feb 10, 2021 00:41 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 538 $68.46 $36,831.48
Disclosure

SEC source: 0001127602-21-004786 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,543

Read SEC document
February 06, 2021 Filed Feb 10, 2021 00:41 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 1,818 $0.00 $0.00
Disclosure

SEC source: 0001127602-21-004786 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,081

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

Read SEC document
January 26, 2021 Filed Jan 29, 2021 00:45 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 878 $66.70 $58,562.60
Disclosure

SEC source: 0001127602-21-002910 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,263

Read SEC document
January 26, 2021 Filed Jan 29, 2021 00:45 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantCommon Stock 2,941 $0.00 $0.00
Disclosure

SEC source: 0001127602-21-002910 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,141

F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2018. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

Read SEC document
January 26, 2021 Filed Jan 29, 2021 00:45 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantCommon Stock 12,914 $0.00 $0.00
Disclosure

SEC source: 0001127602-21-002910 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,200

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 6, 2019, and March 10, 2020. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

Read SEC document
November 10, 2020 Filed Nov 12, 2020 22:50 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 1,913 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-20-028870 · form4.xml · derivative · entry 5

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,118

Underlying: Common Stock · 1,913 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

Read SEC document
November 10, 2020 Filed Nov 12, 2020 22:50 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 1,133 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-20-028870 · form4.xml · derivative · entry 4

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,031

Underlying: Common Stock · 1,133 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested.

Read SEC document
November 10, 2020 Filed Nov 12, 2020 22:50 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 1,399 $60.62 $84,807.38
Disclosure

SEC source: 0001127602-20-028870 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,286

Read SEC document
November 10, 2020 Filed Nov 12, 2020 22:50 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 1,913 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-20-028870 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,685

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

Read SEC document
November 10, 2020 Filed Nov 12, 2020 22:50 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 1,133 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-20-028870 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,772

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

Read SEC document
August 10, 2020 Filed Aug 12, 2020 20:57 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 2,306 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-20-023463 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,164

Underlying: Common Stock · 2,306 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested.

Read SEC document
August 10, 2020 Filed Aug 12, 2020 20:57 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 1,022 $68.51 $70,017.22
Disclosure

SEC source: 0001127602-20-023463 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,639

Read SEC document
August 10, 2020 Filed Aug 12, 2020 20:57 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 2,306 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-20-023463 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,661

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

Read SEC document
June 10, 2020 Filed Jun 12, 2020 19:28 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 3,646 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-019496 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,470

Underlying: Common Stock · 3,646 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.

Read SEC document
June 10, 2020 Filed Jun 12, 2020 19:28 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 1,691 $77.07 $130,325.37
Disclosure

SEC source: 0001127602-20-019496 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,355

Read SEC document
June 10, 2020 Filed Jun 12, 2020 19:28 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 3,646 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-019496 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,046

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 10, 2020 Filed Mar 13, 2020 00:15 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantRestricted Stock Unit · Derivative 12,100 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-20-010511 · form4.xml · derivative · entry 6

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,116

Underlying: Common Stock · 12,100 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

Read SEC document
March 10, 2020 Filed Mar 13, 2020 00:15 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantNon-qualified Stock Option (Right to Buy) · Derivative 71,850 $0.00 Strike: $72.34 $0.00
Disclosure

SEC source: 0001127602-20-010511 · form4.xml · derivative · entry 5

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,850

Underlying: Common Stock · 71,850 shares

Expires 2030-03-10

F5 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
March 10, 2020 Filed Mar 13, 2020 00:15 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 769 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-20-010511 · form4.xml · derivative · entry 4

Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,016

Underlying: Common Stock · 769 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.